Oligodendroglial tumors

Kurt Jaeckle

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Oligodendroglial tumors are relatively rare, comprising approximately 5% of all glial neoplasms. Oligodendroglial tumor patients have a better prognosis than those with astrocytic neoplasms, and patients with tumors that contain 1p/19q co-deletions or IDH-1 mutations appear to be particularly sensitive to treatment. In the past decade, scientists have made significant progress in the unraveling the molecular events that relate to the pathogenesis of these neoplasms. There is considerable excitement resulting from the recent reports from two large phase III randomized trials (European Organization for Research and Treatment of Cancer [EORTC] 26951 and Radiation Therapy Oncology Group [RTOG] 9402), which disclosed that patients with newly diagnosed 1p/19q co-deleted anaplastic oligodendroglial tumors have a 7+year increase in median overall survival following chemoradiation, as compared to radiation alone. This has stimulated a renewed interest in the development of new therapeutic strategies for treatment and potential cure of oligodendroglial tumors, based on an improved scientific understanding of the molecular events involved in the pathogenesis of these neoplasms. The goal of this document is to summarize the key translational developments and recent clinical therapeutic trial data, with a correlative perspective on current and future directions.

Original languageEnglish (US)
Pages (from-to)468-477
Number of pages10
JournalSeminars in Oncology
Volume41
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Neoplasms
Therapeutics
Radiation Oncology
Neuroglia
Radiotherapy
Clinical Trials
Radiation
Mutation
Survival
Research

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Jaeckle, Kurt. / Oligodendroglial tumors. In: Seminars in Oncology. 2014 ; Vol. 41, No. 4. pp. 468-477.
@article{5665f191c3024b4eb69ea4081dc097ce,
title = "Oligodendroglial tumors",
abstract = "Oligodendroglial tumors are relatively rare, comprising approximately 5{\%} of all glial neoplasms. Oligodendroglial tumor patients have a better prognosis than those with astrocytic neoplasms, and patients with tumors that contain 1p/19q co-deletions or IDH-1 mutations appear to be particularly sensitive to treatment. In the past decade, scientists have made significant progress in the unraveling the molecular events that relate to the pathogenesis of these neoplasms. There is considerable excitement resulting from the recent reports from two large phase III randomized trials (European Organization for Research and Treatment of Cancer [EORTC] 26951 and Radiation Therapy Oncology Group [RTOG] 9402), which disclosed that patients with newly diagnosed 1p/19q co-deleted anaplastic oligodendroglial tumors have a 7+year increase in median overall survival following chemoradiation, as compared to radiation alone. This has stimulated a renewed interest in the development of new therapeutic strategies for treatment and potential cure of oligodendroglial tumors, based on an improved scientific understanding of the molecular events involved in the pathogenesis of these neoplasms. The goal of this document is to summarize the key translational developments and recent clinical therapeutic trial data, with a correlative perspective on current and future directions.",
author = "Kurt Jaeckle",
year = "2014",
month = "1",
day = "1",
doi = "10.1053/j.seminoncol.2014.06.009",
language = "English (US)",
volume = "41",
pages = "468--477",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4",

}

Oligodendroglial tumors. / Jaeckle, Kurt.

In: Seminars in Oncology, Vol. 41, No. 4, 01.01.2014, p. 468-477.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oligodendroglial tumors

AU - Jaeckle, Kurt

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Oligodendroglial tumors are relatively rare, comprising approximately 5% of all glial neoplasms. Oligodendroglial tumor patients have a better prognosis than those with astrocytic neoplasms, and patients with tumors that contain 1p/19q co-deletions or IDH-1 mutations appear to be particularly sensitive to treatment. In the past decade, scientists have made significant progress in the unraveling the molecular events that relate to the pathogenesis of these neoplasms. There is considerable excitement resulting from the recent reports from two large phase III randomized trials (European Organization for Research and Treatment of Cancer [EORTC] 26951 and Radiation Therapy Oncology Group [RTOG] 9402), which disclosed that patients with newly diagnosed 1p/19q co-deleted anaplastic oligodendroglial tumors have a 7+year increase in median overall survival following chemoradiation, as compared to radiation alone. This has stimulated a renewed interest in the development of new therapeutic strategies for treatment and potential cure of oligodendroglial tumors, based on an improved scientific understanding of the molecular events involved in the pathogenesis of these neoplasms. The goal of this document is to summarize the key translational developments and recent clinical therapeutic trial data, with a correlative perspective on current and future directions.

AB - Oligodendroglial tumors are relatively rare, comprising approximately 5% of all glial neoplasms. Oligodendroglial tumor patients have a better prognosis than those with astrocytic neoplasms, and patients with tumors that contain 1p/19q co-deletions or IDH-1 mutations appear to be particularly sensitive to treatment. In the past decade, scientists have made significant progress in the unraveling the molecular events that relate to the pathogenesis of these neoplasms. There is considerable excitement resulting from the recent reports from two large phase III randomized trials (European Organization for Research and Treatment of Cancer [EORTC] 26951 and Radiation Therapy Oncology Group [RTOG] 9402), which disclosed that patients with newly diagnosed 1p/19q co-deleted anaplastic oligodendroglial tumors have a 7+year increase in median overall survival following chemoradiation, as compared to radiation alone. This has stimulated a renewed interest in the development of new therapeutic strategies for treatment and potential cure of oligodendroglial tumors, based on an improved scientific understanding of the molecular events involved in the pathogenesis of these neoplasms. The goal of this document is to summarize the key translational developments and recent clinical therapeutic trial data, with a correlative perspective on current and future directions.

UR - http://www.scopus.com/inward/record.url?scp=84906729202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906729202&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2014.06.009

DO - 10.1053/j.seminoncol.2014.06.009

M3 - Article

C2 - 25173140

AN - SCOPUS:84906729202

VL - 41

SP - 468

EP - 477

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4

ER -